Antibiotic discovery explained: the ideas that matter

01 Selective toxicity is the north star

An antibiotic must harm bacteria more than it harms the patient. This is selective toxicity, not perfect toxicity. Bacterial cell walls, ribosomes and metabolic pathways can create useful differences, but human biology is still exposed to the drug and its consequences.

The idea explains why potency alone is not enough. A compound that kills every cell in a dish may be a poor medicine. Discovery searches for a therapeutic window: enough activity at the infection, with risks that remain acceptable.

02 Nature is a library, not a catalog

Microbes, fungi and plants make chemicals to compete, communicate and defend themselves. Their chemistry is a vast source of clues, but natural products arrive as mixtures, often in tiny amounts and with complicated structures. Synthetic libraries and engineered biology extend the search rather than replace ecology.

Thinking of nature as a library is useful only if we remember that most books are hard to find and many are not medicines. Sampling, culturing, extraction and testing determine which chemistry becomes visible.

03 A screen finds a candidate; evidence finds a drug

High-throughput assays can examine thousands or millions of conditions, but they optimize what the instrument can read. A “hit” may be insoluble, unstable, nonspecific or active only at an impossible concentration.

Validation asks progressively harder questions: does it work in intact bacteria, does the target explanation hold, does it reach the infection, is it tolerated, and does it improve outcomes? Discovery is a ladder of evidence, not a single score.

04 Mechanism is a map for action

Knowing a target or pathway makes the result intelligible. It can explain spectrum, predict resistance, suggest combinations and guide chemical optimization. But mechanism should be established by converging evidence; a plausible binding story is not automatically the whole biological explanation.

Mechanistic understanding also limits overclaiming. If a drug blocks cell-wall assembly, that does not mean every bacterium is equally vulnerable. Cell envelope structure, growth rate, physiological state and access all shape the observed effect.

05 Exposure connects chemistry to patients

Pharmacokinetics describes where the drug goes and how long it remains. Pharmacodynamics describes how exposure changes bacterial growth or killing. Together they turn a laboratory concentration into a dosing question.

This is why “strong in vitro” and “effective in patients” are different claims. Protein binding, tissue barriers, immune response, dose timing and infection location can all change the relationship between an assay and an outcome.

06 Resistance is evolutionary feedback

When an antibiotic removes susceptible bacteria, variants or gene-bearing cells with survival advantages can become more common. Bacteria can also acquire resistance genes from other bacteria. The drug changes the population, and the changed population changes what the drug can do.

That feedback does not make antibiotics useless; it makes use part of discovery. Mechanism, dose, duration, diagnostics and surveillance should be considered together so that treatment is effective without creating avoidable selection pressure.

07 The pipeline is a translation problem

Discovery translates between scales: molecule, cell, tissue, patient, hospital and population. Each scale has its own evidence and failure modes. A successful candidate survives the translation without losing its therapeutic meaning.

The practical takeaway is a disciplined vocabulary. Say “hit” when it is a hit, “candidate” when it is a candidate, and “clinical benefit” only when appropriate evidence supports it. Clear labels protect both science and the people who rely on it.